Breast cancer (Tokyo, Japan)

Keyphrases

Publications

2023

Hanxi Zhang, Jamie C Barner, Leticia R Moczygemba, Karen L Rascati, Chanhyun Park, Dhatri Kodali
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis. Breast cancer (Tokyo, Japan) (2023)
Hideko Yamauchi, Masakazu Toi, Shin Takayama, Seigo Nakamura, Toshimi Takano, Karen Cui, Christine Campbell, Liesbet De Vos, Charles Geyer, Andrew Tutt
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial. Breast cancer (Tokyo, Japan) (2023)
Maria Donatella Mariniello, Matteo Ghilli, Benedetta Favati, Irini Gerges, Livio Colizzi, Margherita Tamplenizza, Alessandro Tocchio, Federico Martello, Maria Ghilardi, Maria Cristina Cossu, Serena Danti, Manuela Roncella
Cell-free biomimetic polyurethane-based scaffold for breast reconstruction following non-malignant lesion resection. A first-in-human study. Breast cancer (Tokyo, Japan) (2023)
Jing-Jing Li, Yue Yu, Jie Ge
HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast cancer (Tokyo, Japan) (2023)
Kenji Tamura, Toru Mukohara, Kan Yonemori, Yumiko Kawabata, Xavier Nicolas, Tomoyuki Tanaka, Hiroji Iwata
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2). Breast cancer (Tokyo, Japan) (2023)
Murat Akyol, Alper Tuğral, Zeynep Arıbaş, Yeşim Bakar
Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study. Breast cancer (Tokyo, Japan) (2023)
Samia Kada Mohammed, Oumar Billa, Sylvain Ladoire, Clementine Jankowski, Isabelle Desmoulins, Marie-Laure Poillot, Charles Coutant, Françoise Beltjens, Sandrine Dabakuyo, Laurent Arnould
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study. Breast cancer (Tokyo, Japan) (2023)
Jiulong Ma, Fengjun Wang, Chen Chen, Jiahua Ji, Peng Huang, Dexian Wei, Yang Zhang, Liqun Ren
Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer. Breast cancer (Tokyo, Japan) (2023)
Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) (2023)
Shigeru Imoto, Kun Wang, Xi-Wen Bi, Guangyu Liu, Young-Hyuck Im, Seock-Ah Im, Sung Hoon Sim, Takayuki Ueno, Manabu Futamura, Masakazu Toi, Yasuhiro Fujiwara, Sung Gwe Ahn, Jeong Eon Lee, Yeon Hee Park, Shintaro Takao, Mari Saito Oba, Yuko Kitagawa, Masahiko Nishiyama
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1). Breast cancer (Tokyo, Japan) (2023)
Shun Kawaguchi, Keiichi Kinowaki, Nobuko Tamura, Tomohiko Masumoto, Aya Nishikawa, Akio Shibata, Kiyo Tanaka, Yoko Kobayashi, Takuya Ogura, Junichiro Sato, Hidetaka Kawabata
High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging. Breast cancer (Tokyo, Japan) (2023)
Tomohiro Ochi, Atsushi Yoshida, Osamu Takahashi, Yuka Kajiura, Junko Takei, Naoki Hayashi, Hiroyuki Takei, Hideko Yamauchi
Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis. Breast cancer (Tokyo, Japan) (2023)
Yoshihiro Sowa, Naoki Inafuku, Itaru Tsuge, Hiroki Yamanaka, Motoki Katsube, Michiharu Sakamoto, Ichiro Nakayama, Naoki Morimoto
Development and implementation of a decision aid for post-mastectomy breast reconstruction for Japanese women with breast cancer: a field-testing study. Breast cancer (Tokyo, Japan) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) (2023)
Xin Qing, Chunlei Yuan, Ke Wang
Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer. Breast cancer (Tokyo, Japan) (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) (2023)
Yan Li, Feiyang Na, Jianying Pei
Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification. Breast cancer (Tokyo, Japan) (2023)
Tsunehisa Nomura, Masaaki Kawai, Yuna Fukuma, Yoshikazu Koike, Shinji Ozaki, Motoki Iwasaki, Seiichiro Yamamoto, Kiyoshi Takamatsu, Hitoshi Okamura, Masami Arai, Shoichiro Ootani, Hiroji Iwata, Shigehira Saji
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition. Breast cancer (Tokyo, Japan) (2023)
Mikinao Oiwa, Namiko Suda, Takako Morita, Yuko Takahashi, Yasuyuki Sato, Takako Hayashi, Aya Kato, Rieko Nishimura, Shu Ichihara, Tokiko Endo
Validity of computed mean compressed fibroglandular tissue thickness and breast composition for stratification of masking risk in Japanese women. Breast cancer (Tokyo, Japan) (2023)
Masayuki Nagahashi, YiWei Ling, Chie Toshikawa, Tetsu Hayashida, Yuko Kitagawa, Manabu Futamura, Takashi Kuwayama, Seigo Nakamura, Hideko Yamauchi, Teruo Yamauchi, Koji Kaneko, Chizuko Kanbayashi, Nobuaki Sato, Junko Tsuchida, Kazuki Moro, Masato Nakajima, Yoshifumi Shimada, Hiroshi Ichikawa, Stephen Lyle, Yasuo Miyoshi, Kazuaki Takabe, Shujiro Okuda, Toshifumi Wakai
Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. Breast cancer (Tokyo, Japan) (2023)
Christine Song, Ayse Tuba Kendi, Ji Yeon Shim, Dawa Jung, Pil Soo Kang, Val J Lowe, SeungBaek Lee
ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor. Breast cancer (Tokyo, Japan) (2023)
Jun Watanabe, Yuki Kataoka, Akira Koike, Atsushi Miki, Mikio Shiozawa, Masako Sakuragi, Michiko Harao, Joji Kitayama, Naohiro Sata
Efficacy and safety of surgical energy devices for axillary node dissection: a systematic review and network meta-analysis. Breast cancer (Tokyo, Japan) (2023)
Nobumoto Tomioka, Kanako C Hatanaka, Dai Okuyama, Ken-Ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region. Breast cancer (Tokyo, Japan) (2023)
Fan Wang, Linghui Fang, Bifei Fu, Chen Fan
Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes. Breast cancer (Tokyo, Japan) (2023)
Fernando Hernanz, González Noelia, Esteban Maria, Muñoz Pedro
Centrally located breast carcinomas treated with central quadrantectomy and immediate nipple-areola reconstruction: a cohort study. Breast cancer (Tokyo, Japan) (2023)
Mari Kikuchi, Naoya Gomi, Arisa Ueki, Tomo Osako, Takashi Terauchi
Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study. Breast cancer (Tokyo, Japan) (2023)
Kou Kou, Jessica Cameron, Philippa Youl, Chris Pyke, Suzanne Chambers, Jeff Dunn, Joanne F Aitken, Peter David Baade
Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study. Breast cancer (Tokyo, Japan) (2023)
Nobumoto Tomioka, Kanako C Hatanaka, Dai Okuyama, Ken-Ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi
Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region. Breast cancer (Tokyo, Japan) (2023)
Shozo Ohsumi, Kenichi Watanabe, Naoto Kondo, Yoshimasa Kosaka, Takashi Ishikawa, Miyuki Kitahara, Shinichiro Kubo, Mari S Oba, Tetsuya Kimura, Atsushi Takita, Hirofumi Mukai
Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry. Breast cancer (Tokyo, Japan) (2023)
Kazumi Jinbo, Takaaki Fujita, Ryuichi Kasahara, Ryohei Jinbo, Sayaka Kisara, Jun Onobe, Izo Kimijima, Mitsuhiko Yasuda, Yuichi Yamamoto
The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees. Breast cancer (Tokyo, Japan) (2023)
Fa Jiang, Lifeng Yang, Xiong Jiao
Dynamic network biomarker to determine the critical point of breast cancer stage progression. Breast cancer (Tokyo, Japan) (2023)

volume 30, number 2, 2023

Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Manabu Futamura, Kazuhiro Ishihara, Yasuko Nagao, Atsuko Ogiso, Yoshimi Niwa, Takumi Nakada, Yoshihiro Kawaguchi, Ai Ikawa, Iwao Kumazawa, Ryutaro Mori, Mai Kitazawa, Yoshiki Hosono, Masashi Kuno, Mana Kawajiri, Akira Nakakami, Makoto Takeuchi, Akemi Morikawa, Yoshihisa Tokumaru, Yasuo Katagiri, Yoshimasa Asano, Yoshinori Mushika, Toshio Shimokawa, Nobuhisa Matsuhasih
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04). Breast cancer (Tokyo, Japan) 30 (2) (2023)
Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Mohammed Tarek Hasan, Mohamed Hamouda, Mohammad K El Khashab, Ahmed Bostamy Elsnhory, Abdullah Mohamed Elghamry, Obada Atef Hassan, Aya Mamdouh Fayoud, Abdelrahman H Hafez, Mohammed Al-Kafarna, Abdulrahman Ibrahim Hagrass, Randa Kamal Rabea, Mohamed Ibrahim Gbreel
Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Laetitia Collet, Lauriane Eberst, Gauthier Ludovic, Marc Debled, Loana Hrab, Marie-Ange Mouret-Reynier, Isabelle Desmoulins, Anthony Goncalves, Mario Campone, Jean-Marc Ferrero, Etienne Brain, Lionel Uwer, Jean-Christophe Eymard, Veronique Dieras, Gaetane Simon, Marianne Leheurteur, Florence Dalenc, Laurence Vanlemmens, Amelie Darlix, Monica Arnedos, Thomas Bachelot
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)
Caroline Bailleux, Antoine Arnaud, Jean-Sébastien Frenel, Sylvie Chabaud, Thomas Bachelot, Benoît You, Laëtitia Stefani, Claire Garnier Tixidre, Hélène Simon, Dominique Beal-Ardisson, Jean-Philippe Jacquin, Francesco Del Piano, Alain Lortholary, Claudiu Cornea, Charlotte Greilsamer, Rémy Largillier, Fabien Brocard, Eric Legouffe, Mustapha Atlassi, Anne-Claire Hardy-Bessard, Pierre-Etienne Heudel
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients. Breast cancer (Tokyo, Japan) 30 (2) (2023)